Advanced search for publications
Enter your keywords
Clascoterone for the treatment of acne vulgaris
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. The aim of this publication is to evaluate the efficacy, safety and potential place in therapy of Clascoterone cream a first-in-class androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. […]
Fezolinetant for treating vasomotor symptoms associated with the menopause
A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making April 2025 MHRA Drug Safety Update – Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. […]
Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women
Download the full review below to read more. A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making.
Estradiol spray for the treatment of menopausal symptoms
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Download the full review below to read more.
Fast acting insulin lispro for the treatment of diabetes mellitus
Overview New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Ultra-rapid acting insulin lispro (Lyumjev®▼, Lilly) is a new formulation of insulin lispro with added treprostinil and citrate to produce a more […]
Oral semaglutide for the treatment of type 2 diabetes mellitus
Semaglutide (Rybelsus®▼) is the first oral GLP1 receptor agonist (GLP1RA), for the treatment of adults with type 2 diabetes mellitus. Download the full review below to read more.
Brolucizumab for wet age-related macular degeneration
Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks. Download the full review below to read more.
Levodopa inhalation powder for episodic motor fluctuations in Parkinson’s disease
Inbrija®▼ (Acorda Therapeutics), a levodopa powder for oral inhalation, is licensed for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Naldemedine for the treatment of opioid induced constipation
Naldemedine is the second oral peripherally acting μ-opioid receptor antagonist to be launched,after naloxegol. It is licensed for the treatment of opioid induced constipation (OIC) in adults whohave previously been treated with laxatives.
Pentosan for the treatment of bladder pain syndrome
Pentosan polysulfate sodium capsules (Elmiron®, Consilient Health) are indicated for the treatment of bladder pain syndrome characterised by glomerulations or Hunner’s lesions. Download the full review below to read more.